This is a working overview of freeze-thaw, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-29 and is reviewed periodically as new material appears.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
=== Name === Within the INN, USAN, BAN, and AAN naming systems this drug is known as butorphanol, while within JAN it is named torbugesic. As the tartrate salt, butorphanol is known as butorphanol tartrate (USAN, BAN).
=== Angiofibromas === Sirolimus has been used as a topical treatment of angiofibromas with tuberous sclerosis complex (TSC). Facial angiofibromas occur in 80% of patients with TSC, and the condition is very disfiguring. A retrospective review of English-language medical publications reporting on topical sirolimus treatment of facial angiofibromas found sixteen separate studies with positive patient outcomes after using the drug. The reports involved a total of 84 patients, and improvement was observed in 94% of subjects, especially if treatment began during the early stages of the disease. Sirolimus treatment was applied in several different formulations (ointment, gel, solution, and cream), ranging from 0.003 to 1% concentrations. Reported adverse effects included one case of perioral dermatitis, one case of cephalea, and four cases of irritation. In April 2022, sirolimus was approved by the FDA for treating angiofibromas.
We will keep pressing. We will keep pushing, keep advancing, no quarter, no mercy for our enemies. Yet some in this crew, in the press, just can't stop. Allow me to make a few suggestions. People look up at the TV and they see banners, they see headlines. I used to be in that business. And I know that everything is written intentionally.For example, a banner or a headline: "Mideast war intensifies," splashing on the screen the last couple of days, alongside visuals of civilian or energy targets that Iran has hit, because that's what they do. What should the banner read instead?How about, 'Iran increasingly desperate,' because they are. They know it and so do you, if it can be admitted. Or more fake news from CNN, "reports that the Trump administration underestimated the Iran war's impact on the Strait of Hormuz" – patently ridiculous, of course. For decades, Iran has threatened shipping in the Strait of Hormuz.This is always what they do, hold the strait hostage. CNN doesn't think we thought of that. It's a fundamentally unserious report. The sooner David Ellison takes over that network, the better.Another example of a fake headline that I saw yesterday, "war widening." Here's a real headline for you, for an actual patriotic press: how about, 'Iran shrinking, going underground'? You see, Iran's leaders are hiding in bunkers and moving into civilian areas. The only thing that is widening is our advantage, not to mention our Gulf partners stepping up even more, now going on the offense, and have always been with us on the defense with collective and integrated air defenses.
== Career == Armstrong began his academic career at Rosalind Franklin University of Medicine and Science, where he served as Professor of Surgery and Associate Dean at the Scholl College of Podiatric Medicine. He later moved to Tucson and accepted an offer at the University of Arizona. In 2017, Armstrong was honored as University Distinguished Outreach Professor of Surgery—the first ever in the history of the University of Arizona's Department of Surgery. Following the University of Arizona, Armstrong accepted a position at the Keck School of Medicine of the University of Southern California's Department of Surgery, where he was later named Distinguished Professor of Surgery and Neurological Surgery. In 2025, USC bestowed upon Armstrong the title of Distinguished Professor—one of the university's highest academic honors—making him the first Doctor of Podiatric Medicine to receive this distinction at USC.
A guide bar, typically an elongated bar with a round end of wear-resistant alloy steel typically 40 to 90 cm (15.5 to 35.5 in) in length, is used. An edge slot guides the cutting chain. Specialized, loop-style bars, called bow bars, were also used at one time for bucking logs and clearing brush, although they are now rarely encountered due to increased hazards of operation. The lower part of the chain runs in the gauge. Here, the lubrication oil is pulled by the chain to the nose. This is basically the thickness of the drive links.
Sources: en.wikipedia.org
=== Bacteria === All taxonomic kingdoms have examples of xerophiles. Microbial xerophiles will usually inhabit environments that are sugar-rich or salt-rich, and xerophilic bacteria will most commonly be found in salt rich areas. Because xerophiles often live in salt-rich environments many halophilic species such as H. halophila, Bacillus halophilus, and H. salina are often also xerophilic.
=== Ancient === 350 BCE — The Greek philosopher Aristotle, arguably the first philosopher to make a serious attempt to scientifically explain aging, proposes his thesis on aging. He suggests that aging is a process by which human and animal bodies, which are naturally hot and wet, gradually become dry and cold, and theorizes that more moisture delays aging. 259–210 BCE — years of life of the Chinese emperor Qin Shi Huang, who united China under his rule. All his life he persistently searched for an elixir of youth and died trying, presumably taking "pills of immortality", containing mercury. 156–87 BCE — years of life of the Chinese emperor Wu of Han, who persistently tried to find a way to achieve immortality, mainly by means of magic. He used services of various magicians. But Wu of Han was not a naive person – he thoroughly rechecked their abilities and if he identified the person as a quack, he executed him. 63 BC–14 CE — years of life of Caesar Augustus, the first Roman emperor, who is considered one of the most effective leaders of the Ancient Rome. For him an eternal youth was an obsession. In particular, contrary to the Roman tradition to create statues as realistic as possible, he always ordered to portray himself young. There are many of his "youthful" statues but researchers still do not know how he looked in old age. 3rd–17th century — the period of alchemy. There are several directions in alchemy, and it was distributed over a huge territory.
writhing number (W) Also writhe. An index of the superhelical coiling of a DNA molecule. The writhing number does not have a precise quantitative definition but instead represents the degree of supercoiling. Together, the writhing number and the twisting number determine the linking number.
==== Artificial Pancreas (AP) Systems ==== In 2006, Breakthrough T1D launched the Artificial Pancreas Consortium, allocating $6 million in grants to investigate the benefits of technology controlling blood-glucose levels to accelerate the availability of the artificial pancreas (AP). AP systems integrate three components—a CGM, an insulin pump, and an algorithm—to measure blood sugar, then calculate and administer, or withhold, insulin with minimal user input. In 2016, the FDA approved the first hybrid closed-loop, or AP, system.
=== Prenatal diagnostic testing === The preferred prenatal diagnostic method is molecular analysis which requires a mutational analysis to measure BCKAD (branched-chain alpha-keto acid dehydrogenase) enzyme activity in chorion villus cells or amniocytes. Another measurement method is BCAA (branched-chain amino acid) concentration in amniotic fluids.
Sources: en.wikipedia.org
Natural uranium (NU or Unat) is uranium with the same isotopic ratio as found in nature. It contains 0.711% uranium-235, 99.284% uranium-238, and a trace of uranium-234 by weight (0.0055%). Approximately 2.2% of its radioactivity comes from uranium-235, 48.6% from uranium-238, and 49.2% from uranium-234. Natural uranium can be used to fuel both low- and high-power nuclear reactors. Historically, graphite-moderated reactors and heavy water-moderated reactors have been fueled with natural uranium in the pure metal (U) or uranium dioxide (UO2) ceramic forms. However, experimental fuelings with uranium trioxide (UO3) and triuranium octaoxide (U3O8) have shown promise. The 0.72% uranium-235 is not sufficient to produce a self-sustaining critical chain reaction in light water reactors or nuclear weapons; these applications must use enriched uranium. Nuclear weapons take a concentration of 90% uranium-235, and light water reactors require a concentration of roughly 3% uranium-235. Unenriched natural uranium is appropriate fuel for a heavy-water reactor, like a CANDU reactor. On rare occasions, earlier in geologic history, when uranium-235 was more abundant, uranium ore was found to have naturally engaged in fission, forming natural nuclear fission reactors. Uranium-235 decays at a faster rate (half-life of 700 million years) compared to uranium-238, which decays extremely slowly (half-life of 4.5 billion years). Therefore, a billion years ago, there was more than double the uranium-235 compared to now.
Greater Manchester Police confirm that, following their investigation, Labour deputy leader Angela Rayner will not face any further police action over her living arrangements before her time as an MP. Former Plaid Cymru MP Jonathan Edwards, who represents Carmarthen East and Dinefwr, announces he will not contest his seat at the election; Edwards was asked to leave Plaid in 2022 after accepting a police caution for assaulting his wife. Stormont passes the 2024 Northern Ireland budget, its first in three years, despite opposition from the Ulster Unionist Party, and the Assembly's official opposition, the Social Democratic and Labour Party. 29 May – MSPs vote 64–0 to exclude Scotland's former health secretary, Michael Matheson, from the Scottish Parliament for 27 sitting days, and to suspend his salary for 54 days, after he breached expenses rules by accumulating an £11,000 bill on his parliamentary iPad. The governing SNP abstains from voting, and calls for a review of the complaints procedure, suggesting it could be open to bias. The Welsh Conservatives table a motion of no confidence in First Minister Vaughan Gething following several weeks of controversy over donations to his leadership campaign. The motion is scheduled to face a Senedd vote on 5 June. Pat Cullen stands down as chief executive of the Royal College of Nursing in order to seek the nomination as Sinn Féin candidate for Fermanagh and South Tyrone in the general election.
Brenipatide (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name LY-3537031) is a dual agonist of glucagon-like peptide-1 (GLP-1) receptors and gastric inhibitory polypeptide (GIP) receptors. Brenipatide is under development by Eli Lilly and Company for the treatment of alcoholism, bipolar disorder, asthma, smoking withdrawal, cardiovascular disorders, liver disorders, metabolic disorders, and obesity. It is taken by subcutaneous injection once per month. The drug has a longer elimination half-life than tirzepatide or retatrutide. As of December 2025, it was in phase 3 clinical trials for alcoholism and bipolar disorder, phase 2 trials for asthma and smoking withdrawal, and phase 1 trials for cardiovascular disorders, liver disorders, metabolic disorders, and obesity. List of investigational antipsychotics List of investigational bipolar disorder drugs List of investigational substance-related disorder drugs
== Civilian applications == Depleted uranium has a very high density and is primarily used as shielding material for other radioactive material, and as ballast. Examples include sailboat keels, as counterweights and as shielding in industrial radiography cameras.
== External links == Media related to Anti-obesity drugs at Wikimedia Commons Prescription Medications to Treat Overweight & Obesity US National Institute of Diabetes and Digestive and Kidney Diseases
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
Short transit at ambient temperature is generally tolerated, but long-term storage at room temperature is not recommended. Heat, moisture, and light all accelerate degradation. Cold, dry, dark storage is the conventional choice.